ALDX
Aldeyra Therapeutics, Inc.Company with tickers: ALDX
CIK
1341235
CUSIP
01438T106
Shares Outstanding
60,321,068
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $2,409,575 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-3,546,918 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-3,452,619 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.06 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.06 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |